From May 11-15th 2025, the 26th International Society for Radiopharmaceutical Sciences (iSRS 2025) grandly opened on the Gold Coast of Australia. This is the conference's return to Australia after 22 years since it was held in Sydney in 2003. It has attracted thousands of scientists, clinical experts, and leading enterprises in the industry from around the world to jointly discuss cutting-edge topics such as the research and development of radiopharmaceuticals, the application of isotope technology, and innovation in tumor diagnosis and treatment.
The Gold Coast: A Perfect Integration of Science and Nature
The Gold Coast is renowned for its sunny beaches, surfing spots, and rich ecological landscapes. The conference venue is located in the core coastal area, and participants can walk to the beach to experience the unique Australian leisure culture. In addition to academic activities, the organizing committee has specially planned distinctive activities such as surfing courses and visits to the Advanced Imaging Centre of the University of Queensland to promote academic exchanges and cross-cultural interactions. Giancarlo Pascali, iSRS 2025 Program Chair, said, "We hope to create a platform that inspires global scholars through top-notch scientific content and a unique natural environment."
United Well: Demonstrating the Innovative Achievements of the Integrated Nuclear Medicine Industry Chain
As an innovative representative in China's nuclear medicine field, United Well released an "Integrated Precision Diagnosis and Treatment" solution during iSRS 2025, covering the development, production, and supply of radiopharmaceuticals and isotopes for diagnosis and treatment.
Promoting Industry Collaboration and Building the Future of Nuclear Medicine
Michael Kassioui, iSRS 2025 Program Co-Chair, emphasized, "Radiopharmaceuticals are moving from a 'niche technology' to the mainstream battlefield of tumor diagnosis and treatment." In this battle against tumors, more enterprises with innovative vitality and pioneering spirit are needed. By relying on breakthroughs in cutting-edge technologies and cross-regional resource integration, a globally collaborative R&D network should be established to provide more accessible solutions for patients worldwide. During this exhibition, United Well focused on showcasing the clinical transformation achievements of its α radiopharmaceuticals. The company plans to cooperate with research institutions in the United States to develop targeted isotope drugs for tumors that are highly prevalent in the Asia-Pacific region and explore the localized construction of the medical isotope supply chain in Asia.
As the conference agenda progresses step by step, the global nuclear medicine community is focusing its attention on the Gold Coast. This grand event, where science and industry resonate with each other, is likely to become another important milestone in the journey of radiopharmaceuticals in conquering cancer.
